CelLBxHealth PLC (AIM:CLBX, OTCQB:ANPCF) has wrapped up its latest retail fundraise, bringing in about £960,000 as part of a wider financing package designed to support the diagnostics company’s plans to scale.
The AIM-quoted group, which focuses on analysing circulating tumour cells, cancer cells that break away from a tumour and enter the bloodstream, said the retail offer launched last week is now closed.
Just under 96 million new shares will be issued at 1 pence each, provided shareholders approve the move at a general meeting on 15 December.
Today’s update means CellbxHealth has, in total, conditionally raised around £7.8 million through a mixture of placing, subscription and retail fundraising.
If the resolutions pass, the company will issue roughly 776 million new shares, increasing its total share count to a little under 1.1 billion.
The new shares are scheduled to begin trading in two stages. The first tranche, just over 9 million shares, is expected to join the market on 16 December. The second and much larger tranche, covering the placing, subscription and retail shares, is due to follow on 18 December. Both dates could be pushed back, but only as far as mid-January.
The company has promised a further announcement after the shareholder vote, confirming the result and setting out the updated voting rights.